| A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma (NCT07637578) | SCRI Development Innovations, LLC | 2026-08-01 |
| A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL) (NCT07011576) | SCRI Development Innovations, LLC | 2025-09-29 |
| Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma (NCT06974786) | SCRI Development Innovations, LLC | 2025-08-08 |
| BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS) (NCT06773910) | SCRI Development Innovations, LLC | 2025-03-11 |
| Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib (NCT05948462) | SCRI Development Innovations, LLC | 2023-11-01 |
| Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma (NCT05972135) | SCRI Development Innovations, LLC | 2023-10-23 |
| Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer (NCT05748834) | SCRI Development Innovations, LLC | 2023-07-24 |
| A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer (NCT04699630) | SCRI Development Innovations, LLC | 2021-05-03 |
| A Study of Itacitinib for the Treatment of Chronic Graft Versus Host Disease (cGVHD) (NCT04200365) | SCRI Development Innovations, LLC | 2020-06-05 |
| A Study of CPX-351 (Vyxeos™) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid Leukemia (NCT04209725) | SCRI Development Innovations, LLC | 2020-06-03 |
| Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant Cyclophosphamide (NCT04361058) | SCRI Development Innovations, LLC | 2020-04-13 |
| Nivolumab Maintenance Therapy After Autologous Stem Cell Transplant in Hodgkin Lymphoma Pts at Relapse/Progression Risk (NCT03436862) | SCRI Development Innovations, LLC | 2018-05-23 |